Literature DB >> 29904936

TPX2 gene silencing inhibits cell proliferation and promotes apoptosis through negative regulation of AKT signaling pathway in ovarian cancer.

Yuan Tian1, Lian-Lian Liu1, Dong-Mei Guo1, Yan Wang1, Wen-Hui Zha1, Yang Li1, Fu-Ju Wu1.   

Abstract

Ovarian cancer (OC) is the leading cause of death from gynecological malignancy. Accumulated studies have revealed that targeting protein for Xklp2 (TPX2) was tightly associated with the development and progression of OC. The present study further determined a novel mechanism of TPX2 in OC via the AKT signaling pathway. The differentially expressed genes were screened in GEO database for gene expression microarray of OC. Bioinformatics was used to analyze the key differentially expressed genes in OC. We prepared CD133/1+ OC stem cells. Then cells were treated with TPX2-1 siRNA and perifcsine to explore the correlation of TPX2 and the AKT signaling pathway. We determined the expression of TPX2, AKT, Pl3 K, PTEN, caspase-3, Bax and Bcl-2 in OC cells. Cell proliferation, migration, invasion, and apoptosis rate were respectively measured using MTT and EdU assays, Transwell assay, Scratch test, and flow cytometry. Xenograft tumor in nude mice was used to determine the effect of TPX2 in OC cells in vitro. Initially, TPX2 overexpression was observed in OC, and TPX2 mediated the effect of the AKT signaling pathway in OC. TPX2 knockdown decreased expression of AKT, Pl3 K, and Bcl-2, and the extent of AKT phosphorylation, but increased expression of PTEN, Caspase-3, and Bax. Furthermore, TPX2 knockdown suppressed OC cell proliferation, migration and invasion, but promoted OC cell apoptosis. Taken together, TPX2 silencing negatively regulates the AKT signaling pathway by which OC cell proliferation was inhibited yet cell apoptosis was accelerated, suggesting a potential therapeutic approach to OC.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  AKT signaling pathway; apoptosis; ovarian cancer; proliferation; targeting protein for Xklp2

Mesh:

Substances:

Year:  2018        PMID: 29904936     DOI: 10.1002/jcb.27065

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  4 in total

1.  Integrated genomics and comprehensive validation reveal drivers of genomic evolution in esophageal adenocarcinoma.

Authors:  Subodh Kumar; Leutz Buon; Srikanth Talluri; Marco Roncador; Chengcheng Liao; Jiangning Zhao; Jialan Shi; Chandraditya Chakraborty; Gabriel Gonzalez; Yu-Tzu Tai; Rao Prabhala; Mehmet K Samur; Nikhil C Munshi; Masood A Shammas
Journal:  Commun Biol       Date:  2021-05-24

2.  TPX2 silencing exerts anti‑tumor effects on hepatocellular carcinoma by regulating the PI3K/AKT signaling pathway.

Authors:  Dan-Hong Huang; Jie Jian; Shuang Li; Yan Zhang; Li-Zhen Liu
Journal:  Int J Mol Med       Date:  2019-10-14       Impact factor: 4.101

3.  RHPN1‑AS1 promotes ovarian carcinogenesis by sponging miR‑485‑5p and releasing TPX2 mRNA.

Authors:  Shoubin Cui; Cui Li
Journal:  Oncol Rep       Date:  2021-04-28       Impact factor: 3.906

4.  TPX2 Serves as a Cancer Susceptibility Gene and Is Closely Associated with the Poor Prognosis of Endometrial Cancer.

Authors:  Jun Wang; Hua Zheng; Hui He; Shuying Meng; Yatian Han; Zhe Su; Hanbing Yan; Yanan Zhang
Journal:  Genet Res (Camb)       Date:  2022-03-16       Impact factor: 1.588

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.